摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-氨基-N-(4-羟基丁基)苯甲酰胺 | 146381-58-0

中文名称
2-氨基-N-(4-羟基丁基)苯甲酰胺
中文别名
——
英文名称
2-amino-N-(4-hydroxybutyl)benzamide
英文别名
N-(4-hydroxybutyl) 2-aminobenzamide;N-(4-hydroxybutyl)(2-aminophenyl)formamide
2-氨基-N-(4-羟基丁基)苯甲酰胺化学式
CAS
146381-58-0
化学式
C11H16N2O2
mdl
——
分子量
208.26
InChiKey
IZQZOBYFAMJZOU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    449.0±30.0 °C(Predicted)
  • 密度:
    1.162±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    0.7
  • 重原子数:
    15
  • 可旋转键数:
    5
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.36
  • 拓扑面积:
    75.4
  • 氢给体数:
    3
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    2-氨基-N-(4-羟基丁基)苯甲酰胺 在 bis[dichloro(pentamethylcyclopentadienyl)iridium(III)] 、 三氟甲磺酸 作用下, 以 5,5-dimethyl-1,3-cyclohexadiene 为溶剂, 反应 24.0h, 以68%的产率得到脱氧鸭嘴花碱酮
    参考文献:
    名称:
    Efficient syntheses of 2,3-disubstituted natural quinazolinones via iridium catalysis
    摘要:
    天然产物癸肟酮、佩加美宁、脱氧瓦西酮、麦克那佐啉酮和鲁塔卡平被合成。核心喹嗪啉酮结构通过铱催化构建。
    DOI:
    10.1039/c2ob07178a
  • 作为产物:
    描述:
    靛红酸酐4-氨基-1-丁醇1,4-二氧六环 为溶剂, 反应 6.0h, 以95%的产率得到2-氨基-N-(4-羟基丁基)苯甲酰胺
    参考文献:
    名称:
    Efficient syntheses of 2,3-disubstituted natural quinazolinones via iridium catalysis
    摘要:
    天然产物癸肟酮、佩加美宁、脱氧瓦西酮、麦克那佐啉酮和鲁塔卡平被合成。核心喹嗪啉酮结构通过铱催化构建。
    DOI:
    10.1039/c2ob07178a
点击查看最新优质反应信息

文献信息

  • Triazolo and derivatives as chemokine inhibitors
    申请人:Toray Industries, Inc.
    公开号:US06492364B1
    公开(公告)日:2002-12-10
    Novel triazolo derivatives represented by the following formula and pharmaceutically acceptable salts thereof, as well as chemokine inhibitors containing the same as an effective component. These are useful as therapeutic agents for allergic diseases such as bronchial asthma and atopic dermatitis; therapeutic agents for inflammatory diseases such as chronic rheumatoid arthritis; therapeutic agents for autoimmune diseases such as ulcerative colitis and nephritis; and as anti-AIDS drugs.
    由以下公式表示的新颖三唑衍生物及其药用盐,以及含有相同物质作为有效成分的趋化因子抑制剂。这些对于过敏疾病如支气管哮喘和特应性皮炎的治疗剂、慢性类风湿性关节炎等炎症性疾病的治疗剂、溃疡性结肠炎和肾炎等自身免疫疾病的治疗剂以及抗艾滋病药物都是有用的。
  • Fibrate Compounds Having Ppar Agonist Activity
    申请人:Das Saibal Kumar
    公开号:US20080114005A1
    公开(公告)日:2008-05-15
    There are provided derivatives having PPAR agonist activity. The derivatives include compounds and/or their pharmaceutically acceptable salts; the compounds having the formula (I) wherein A has the structure (II) or (III); X is chosen from —CH 2 —, —O—, —NH—, and —S—; Y is chosen from —O—, —NH—, and —S—; Z, which may be located in any position of substitution, is hydrogen or halogen; R 1 and R 2 , which may be the same or different, are independently chosen from hydrogen and C 1 -C 8 alkyl, or R 1 and R 2 together form a carbocyclic ring having from 4 to 6 carbon atoms; R 3 is chosen from hydrogen and C 1 -C 8 alkyl; R 4 , R 5 , and R 6 , which may be the same or different, are independently chosen from hydrogen and C 1 -C 8 alkyl; and n is 1 to 6. Various embodiments and variants are provided. In accordance with other aspects, the invention also provides methods of producing a PPARα agonist activity in a mammal, the methods including administering to the mammal an effective amount of certain derivative(s) of the first aspect of the invention, a method of producing a PPARα agonist activity and a PPARα agonist activity in a mammal, the method including administering to the mammal an effective amount of certain derivative(s); and a pharmaceutical composition that includes the derivative(s) of the first aspect of the invention and one or more pharmaceutically-acceptable excipients. Various embodiments and variants are provided.
    提供了具有PPAR激动剂活性的衍生物。这些衍生物包括化合物和/或其药学上可接受的盐;其中化合物具有公式(I),其中A具有结构(II)或(III);X选择自—CH2—,—O—,—NH—和—S—;Y选择自—O—,—NH—和—S—;Z可以位于任何取代位置,是氢或卤素;R1和R2,可以相同也可以不同,独立地选择自氢和C1-C8烷基,或者R1和R2共同形成具有4到6个碳原子的碳环;R3选择自氢和C1-C8烷基;R4,R5和R6,可以相同也可以不同,独立地选择自氢和C1-C8烷基;n为1到6。提供了各种实施例和变体。根据其他方面,本发明还提供在哺乳动物中产生PPARα激动剂活性的方法,该方法包括向哺乳动物投与某些第一方面的衍生物的有效量,一种产生PPARα激动剂活性的方法和在哺乳动物中的PPARα激动剂活性,该方法包括向哺乳动物投与某些衍生物的有效量;以及包括第一方面的衍生物和一个或多个药学上可接受的辅料的药物组合物。提供了各种实施例和变体。
  • 2-ACYLAMINOBENZAMIDE DERIVATIVES AND PREVENTIVE AND REMEDY FOR DISEASES CAUSED BY THE SUPERMULTIPLICATION OF VASCULAR INTIMAL CELLS
    申请人:KISSEI PHARMACEUTICAL CO., LTD.
    公开号:EP0855387A1
    公开(公告)日:1998-07-29
    The present invention relates to 2-acylaminobenzamide derivatives represented by the general formula: wherein R1, R2, R3, R4 and R5 represent each a hydrogen atom etc.; X represents a vinylene group etc.; B represents a group represented by the general formula:         -N(R6)(R7) wherein R6 and R7 represent each a hydrogen atom etc., a group represented by the general formula:         -NH-(CH2)n-A-R8 wherein A represents a single bond etc.; R8 represents a hydroxy group etc. or a hydroxyamino group which are useful as agents for the prevention and treatment of diseases caused by excessive proliferation of vascular intimal cells.
    本发明涉及由通式表示的 2-酰氨基苯甲酰胺衍生物: 其中R1、R2、R3、R4和R5分别代表氢原子等;X代表乙烯基等;B代表通式所代表的基团: -N(R6)(R7) 其中 R6 和 R7 各自代表一个氢原子等;B 代表由通式表示的基团: -NH-(CH2)n-A-R8 其中 A 代表单键等;R8 代表羟基等或羟基氨基,它们可用作预防和治疗因血管内膜细胞过度增殖而引起的疾病的药物。
  • TRIAZOLO DERIVATIVES AND CHEMOKINE INHIBITORS CONTAINING THE SAME AS THE ACTIVE INGREDIENT
    申请人:TORAY INDUSTRIES, INC.
    公开号:EP1067130A1
    公开(公告)日:2001-01-10
    Novel triazolo derivatives represented by the following formula and pharmaceutically acceptable salts thereof, as well as chemokine inhibitors containing the same as an effective component. These are useful as therapeutic agents for allergic diseases such as bronchial asthma and atopic dermatitis; therapeutic agents for inflammatory diseases such as chronic rheumatoid arthritis; therapeutic agents for autoimmune diseases such as ulcerative colitis and nephritis; and as anti-AIDS drugs.
    由下式代表的新型三唑并衍生物及其药学上可接受的盐,以及以其为有效成分的趋化因子抑制剂。这些药物可用作支气管哮喘和特应性皮炎等过敏性疾病的治疗药物;慢性类风湿性关节炎等炎症性疾病的治疗药物;溃疡性结肠炎和肾炎等自身免疫性疾病的治疗药物;以及抗艾滋病药物。
  • [EN] NOVEL QUINAZOLINONES THAT INHIBIT THE FORMATION OF TAU OLIGOMERS AND THEIR METHOD OF USE<br/>[FR] NOUVELLES QUINAZOLINONES INHIBANT LA FORMATION D'OLIGOMÈRES TAU ET LEUR PROCÉDÉ D'UTILISATION
    申请人:OLIGOMERIX INC
    公开号:WO2018118791A9
    公开(公告)日:2019-08-22
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐